CM
Therapeutic Areas
Lyell Immunopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Rondecabtagene autoleucel (ronde-cel, LYL314) | Relapsed/Refractory Large B-Cell Lymphoma (Third- or Later-Line) | Pivotal |
| LYL273 | Refractory Metastatic Colorectal Cancer | Phase 1 |
Leadership Team at Lyell Immunopharma
LS
Lynn Seely
President and Chief Executive Officer
RK
Rick Klausner
Founder & Chairman of the Board
SR
Stan Riddell
Founder
GL
Gary Lee
Chief Scientific Officer
DS
David Shook
Chief Medical Officer
SS
Smital Shah
Chief Financial and Business Officer
SH
Stephen Hill
Chief Operating Officer
JA
Jarrad Aguirre
Senior Vice President, Medical Affairs
MM
Mark Meltz
General Counsel and Corporate Secretary
BS
Bryan Selby
Senior Vice President, Clinical Development Operations